Bank of America Corp DE Has $13.20 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Bank of America Corp DE cut its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 31.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 296,415 shares of the company's stock after selling 132,953 shares during the quarter. Bank of America Corp DE owned approximately 0.64% of Omnicell worth $13,196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of OMCL. Smartleaf Asset Management LLC increased its stake in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares during the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Omnicell in the fourth quarter worth $37,000. Van ECK Associates Corp increased its stake in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares during the last quarter. Headlands Technologies LLC bought a new stake in Omnicell in the fourth quarter worth $53,000. Finally, First Horizon Advisors Inc. boosted its holdings in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Down 5.0%

OMCL stock opened at $27.34 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.75. The company has a 50-day moving average of $31.12 and a two-hundred day moving average of $39.10. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of 101.26, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The company had revenue of $269.67 million during the quarter, compared to analysts' expectations of $260.18 million. During the same period in the prior year, the company earned $0.03 earnings per share. The business's quarterly revenue was up 9.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Ratings Changes

OMCL has been the subject of a number of recent research reports. Benchmark decreased their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company upgraded shares of Omnicell from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $31.00 to $35.00 in a report on Wednesday, May 14th. StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $46.50.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.